Table 1 Patients charateristics and ENDOD1 expression of 50 prostate cancer patients
From: Identification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer
| Â | Total no. cases (%) | ENDOD1 expression | P-value | |
|---|---|---|---|---|
| Â | Â | Low or none no. cases (%) | High no. cases (%) | Â |
All cases | 50Â (100) | 22Â (100) | 28Â (100) | Â |
Age | Â | Â | Â | Â |
 <69 | 24 (48) | 10 (45.5) | 14 (50) | 0.749 |
 ≥69 | 26 (52) | 12 (54.5) | 14 (50) |  |
PSA (ng/ml) | Â | Â | Â | Â |
 <10 | 25 (50) | 8 (36.4) | 17 (60.7) | 0.196 |
 10–20 | 12 (24) | 6 (27.2) | 6 (21.4) |  |
 >20 | 13(26) | 8(36.4) | 5(17.9) |  |
Clinical T stage | Â | Â | Â | Â |
 cT1 | 37(74) | 15(68.2) | 22(78.6) | 0.443 |
 cT2 | 12(24) | 6(27.3) | 6(21.4) |  |
 cT3 | 1(2) | 1(4.5) | 0(0) |  |
Biopsy Gleason score | Â | Â | Â | Â |
 ≤6 | 25(50) | 9(40.9) | 16(57.1) | 0.191 |
 7 | 13(24) | 5(22.7) | 8(28.6) |  |
 8–10 | 12(26) | 8(36.4) | 4(14.3) |  |
Pathological T stage | Â | Â | Â | Â |
 pT2 | 33(66) | 12(54.5) | 21(75) | 0.292 |
 pT3a | 4(8) | 2(9.1) | 2(7.1) |  |
 pT3b | 13(26) | 8(36.4) | 5(17.9) |  |
Post-op Gleason score | Â | Â | Â | Â |
 ≤6 | 22(44) | 6(27.3) | 16(57.1) | 0.011 |
 7 | 10(20) | 3(13.6) | 7(25) |  |
 8–10 | 18(36) | 13(59.1) | 5(17.9) |  |
Seminal vesicle invasion | Â | Â | Â | |
 Yes | 13(26) | 8(36.4) | 5(17.9) | 0.139 |
 No | 37(74) | 14(63.6) | 23(82.1) |  |
Lymphnode involvement | Â | Â | Â | |
 Yes | 10(20) | 7(31.8) | 3(10.7) | 0.064 |
 No | 40(80) | 15(68.2) | 25(89.3) |  |
Surgical margin status | Â | Â | Â | Â |
 Yes | 9(18) | 7(31.8) | 2(7.2) | 0.024 |
 No | 41(82) | 15(68.2) | 26(92.9) |  |